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Abstract
Introduction: The objective of this study was to evaluate the safety and feasibility of the immediate return of patients
with ST-elevation myocardial infarction (STEMI) to their originating hospitals after primary percutaneous coronary
intervention (PPCI).
Methods: This was a prospective study, conducted between January 2014 and December 2017. All patients with STEMI
who were transferred for PPCI and returned back to their referring hospitals (RB group) were included and compared to
the onsite STEMI population (OS group). Patient’s demographics, PPCI data, bleeding and adverse cardiovascular
events (ACEs) occurring during transfer, hospital stay, and at 1-month follow-up were recorded.
Results: A total of 156 patients in the OS group were compared against 350 patients in the RB group. We found that ﬁrst
medical contact to balloon time and onset of symptoms to balloon time were signiﬁcantly longer in the RB group than in
the OS group [110 ± 67 min vs. 46 ± 35 min ( p < 0.0001) and 366 ± 300 min vs. 312 ± 120 min ( p ¼ 0.04)], respectively.
There were no differences between the RB and OS groups in in-hospital ACEs: 0.3% versus 0% ( p ¼ 0.8) for death, 0.3%
versus 0.6% ( p ¼ 0.79) for reinfarction, 0.6% versus 2% ( p ¼ 0.72) for bleeding, and no reported cases of repeat revascularization; and 30-day ACEs: 0.3% versus 0.6% ( p ¼ 0.82) for death, 0.3% versus 1.2% ( p ¼ 0.68) for reinfarction, 0.6%
versus 2% ( p ¼ 0.74) for bleeding, and 1.1% versus 1.2% ( p ¼ 0.9) for repeat revascularization.
Conclusion: The immediate return of patients with noncomplicated STEMI after PPCI to their referring hospitals is safe
and feasible, and can be used as part of an effective reperfusion strategy.
Keywords: Myocardial infarction, Primary percutaneous coronary intervention

1. Introduction

S

T-elevation myocardial infarction (STEMI) requires an early reperfusion therapy by either
ﬁbrinolysis or primary percutaneous coronary
intervention (PPCI). Of note, PPCI is cost-effective
and has better reperfusion rates when compared to
thrombolytic therapy; hence, it is considered the
treatment of choice for patients with STEMI when

the delay time from STEMI diagnosis to wire
crossing is expected to be less than 120 min [1,2].
Multiple studies have shown that PPCI can signiﬁcantly reduce mortality, reinfarction, and cerebral
complications compared to ﬁbrinolytic treatment
[3,4]. Nevertheless, the restricted availability of
catheterization laboratories, adequate equipment,
and trained personnel still limits its wider adoption
in developing countries. To resolve these
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limitations, patients’ transferring strategies from
non PPCI-capable hospitals to tertiary-care centers
providing PPCI were developed and proven to
improve outcomes in many randomized trials
[5e10]. However, this strategy might result in an
increased number of PPCIs in tertiary-care centers,
which in turn limits the hospital resources, in
particular, bed availability in critical care units.
Therefore, the concept of immediate return of patients to their parent hospitals was implemented.
Few studies investigated the rationale for the sameday return after PPCI. Moreover, most of the prior
studies focused on late transfers after PCI and
excluded patients with STEMI [11e13]. The aim of
the current study was to evaluate the safety and
feasibility of the immediate return of patients with
STEMI after PPCI to their referring hospitals.

2. Methods
2.1. Study population
We conducted a prospective study between January
2014 and December 2017 in a tertiary-care PPCIcapable center in Al-Qassim region (population of 2
million). Although there are 10 peripheral nonPPCI-capable hospitals in the region, only four
centers with a distance of less than 20 km from the
tertiary-care center were involved in the study. All
study participants were enrolled from Qassim Primary Angioplasty Services (QAPAS) program,
which was implemented in 2004 to provide full-time
PPCI access to all eligible STEMI patients.
2.2. Patient selection
All patients with STEMI transferred for PPCI and
returned back to their referring hospitals between
2014 and 2017 were included in the returned back
(RB) group, whereas patients admitted directly from
the emergency department for PPCI during 2017
served as an onsite (OS) control group (Fig. 1). Patients with hemodynamic instability (Killip class III
or IV, cardiogenic shock, intra-aortic balloon pump
insertion, and electrical complications), complicated
PPCI (coronary dissection, no-reﬂow phenomenon,
major bleeding, and multivessel PCI), concomitant
obstructive left main stenosis, and femoral access
without closure device were excluded from the
study. The study protocol was approved by the
institutional ethics committee (Prince Sultan Cardiac Center Qassim), and all patients signed an
informed consent. Demographic data, coronary
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artery disease risk factors, laboratory results, STEMI
location, as well as electrocardiogram and echocardiography variables were reported.
2.3. Coronary angiography and PCI procedures
All transferred patients were accompanied by a
physician and two trained nurses during ambulance
transportation. According to the study protocol, a
loading dose of aspirin 325 mg, clopidogrel 600 mg, and
intravenous heparin 4000 IU were administered during
transportation unless given in the referring hospital.
Radial access was used for coronary angiography in all
patients; however, radial to femoral crossover was
applied in cases of vascular access complications,
spasm, or technical difﬁculties. All the standard coronary angiographic views were obtained to determine
the number of involved vessels, the extent of coronary
artery disease, and the culprit lesion using visual
assessment. If required, a thrombus aspiration and/or
administration of intravenous glycoprotein IIb/IIIa inhibitors was considered [14,15]. Number and size of the
deployed stents and post-stenting dilatation were done
according to the culprit lesion morphology. All procedural complications and thrombolysis in myocardial
infarction (TIMI) ﬂow grades were recorded. After the
procedure, all hemodynamically stable patients
without procedural complications were transferred to
the referring hospital by the same accompanying
medical team.
2.4. Follow-up
Adverse cardiovascular events (ACEs) including reinfarction caused by stent thrombosis or PCI complications, repeat revascularization, electrical complications
(ventricular tachycardia or advanced atrioventricular
block), rehospitalization because of myocardial
ischemia, stroke, and death during hospital stay and at
1 month follow-up were reported for all patients.
2.5. Statistical analysis
The quantitative variables were expressed as
mean ± standard deviation and categorical variable
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Fig. 1. Methodology of the study. LM ¼ Left Main coronary aretry; PPCI ¼ primary percutaneous coronary intervention; STEMI: ST-elevation
myocardial infarction.

were expressed as frequencies. A Student’s t-test
was used to compare continuous variables, whereas
chi-square test was used for comparison between
categorical variables. All statistical analyses were
performed using the SPSS 15.0 (SPSS Inc., Chicago,
IL, USA).

3. Results
3.1. Clinical and angiographic characteristics
Out of 456 patients who were transferred for PPCI
from the referring hospitals, 350 (77%) were clinically stable and comprised the RB group (mean age,
51 ± 9 years; 91.3% male). The control group
comprised 156 patients who were admitted directly
from the emergency department for PPCI (mean
age, 54 ± 9 years; 85% male). We found no signiﬁcant differences between both groups in age, prevalence of coronary artery disease risk factors, and
the location of myocardial infarction (Table 1 and
Fig. 2). The majority of patients had anterior STEMI
(59.5%), followed by inferior (25%), lateral (11.2%),
and other location myocardial infarction (4.3%).
3.2. Coronary angiography and PPCI
The radial approach was used in 94% of patients,
whereas the femoral approach (with the use of
closure device) was applied in 6% of patients. The
prevalence of nonobstructive coronary artery disease, single-vessel disease, two-vessel disease, and
three-vessel disease was 4.3%, 60.7%, 21%, and 14%,

respectively. Among patients with obstructive coronary disease, the culprit vessel was the left anterior
descending coronary artery in 57.2% patients, the
right coronary artery in 23.5% patients, and the left
circumﬂex in 15% patients. Thrombus aspiration
and glycoprotein IIb/IIIa inhibitors were used in
38% and 78% patients, respectively. TIMI III ﬂow
was achieved in 94% of patients after stent deployment. The angiographic characteristics are shown in
Table 2.
3.3. Timing intervals
The ﬁrst medical contact to balloon time and the
onset of symptoms to balloon time were signiﬁcantly longer in the RB group than in the OS group
(110 ± 67 vs. 46 ± 35 min, p < 0.0001) and (366 ± 300
vs. 312 ± 120 min, p ¼ 0.04), respectively. Conversely,
procedural time and post-PPCI in-hospital stay

Table 1. Baseline characteristics.

Age (years)
Men
Diabetes
Hypertension
Dyslipidemia
Smoking
Family history of CAD

Onsite PCI
(N ¼ 156)

Returned back PCI
(N ¼ 350)

p

54 ± 9
133 (85)
46 (29)
48 (30)
18 (11)
58 (37)
6 (3.8)

51 ± 11
319 (91)
102 (29)
121 (34)
5 (2)
135 (38)
20 (5.7)

0.6
0.86
0.84
0.8
0.08
0.9
0.7

Data are presented as mean ± SD or n (%).
CAD ¼ coronary artery disease; PCI ¼ percutaneous coronary
intervention.
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Fig. 2. STEMI location. ACEs ¼ adverse cardiovascular events;
OS ¼ onsite; PPCI ¼ primary percutaneous coronary intervention;
RG ¼ returned back; STEMI: ST-elevation myocardial infarction;
TIMI ¼ thrombolysis in myocardial infarction.

were comparable between both groups (Table 3).
Patients from the RB group were transferred back
within 34 ± 23 min after the procedure completion.
3.4. Adverse cardiac events
During the hospital stay, there were no differences
in ACEs between the RB and OS groups: one (0.3%)
versus zero (0%) ( p ¼ 0.8) for death, one (0.3%)

Table 2. Angiographic and procedural data.
Onsite PCI
(N ¼ 156)

Returned back PCI
(N ¼ 350)

p

STEMI location
Anterior
Inferior
Lateral
Posterior

96 (62)
42 (27)
8 (5)
10 (6)

205 (58)
84 (24)
49 (14)
12 (4)

0.76
0.81
0.12
0.7

Number of vessels
Nonsigniﬁcant CAD
1V-CAD
2V-CAD
3V-CAD
Radial access
Femoral access

6 (3)
99 (64)
37 (24)
14 (9)
141 (90)
15 (10)

19 (5)
205 (59)
70 (20)
56 (16)
334 (96)
16 (4)

0.89
0.66
0.75
0.4
0.8

Culprit vessel
LAD
LCX
RCA
No PCI
TIMI II
TIMI III

91 (58)
21 (13)
38 (26)
6 (3)
4 (2.5)
152 (97.5)

199 (57)
54 (15)
81 (23)
19 (5)
21 (6)
329 (94)

0.89
0.87
0.76
0.8
0.7

Data are presented as n (%).
1 V-CAD ¼ single-vessel CAD; 2 V-CAD ¼ two-vessel CAD; 3 VCAD ¼ three-vessel CAD; CAD ¼ coronary artery disease;
LAD ¼ Left Anterior Descending artery; LCX ¼ Left circumﬂex
artery; PCI ¼ percutaneous coronary intervention; RCA ¼ Right
coronary artery; STEMI ¼ ST-elevation myocardial infarction;
TIMI ¼ thrombolysis in myocardial infarction.
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versus one (0. 6%) ( p ¼ 0.79) for reinfarction, two
(0.6%) versus three (2%) ( p ¼ 0.72) for bleeding, and
two (0.6%) versus ﬁve (3%) ( p ¼ 0.64) for arrhythmias. Similarly, ACEs at 30-day follow-up were
similar between groups: one (0.3%) versus one
(0.6%) ( p ¼ 0.82) for death, one (0.3%) versus two
(1.2%) ( p ¼ 0.68) for reinfarction, two (0.6%) versus
three (2%) ( p ¼ 0.74) for bleeding, four (1.9%) versus
six (3.8%) ( p ¼ 0.8) for arrhythmias, four (1.1%)
versus two (1.2%) ( p ¼ 0.9) for repeat revascularization, and ﬁve (1.5%) versus seven (4.5%) ( p ¼ 0.57)
for readmission, respectively (Table 4). Importantly,
no ACEs were reported during transfer of the RB
patients to their parent hospitals.

4. Discussion
In the present study, we demonstrated that
retransferring patients after STEMI treated by PPCI
is feasible in 77% of patients. Furthermore, we
found that this strategy might be effective and safe
in the low-risk STEMI population with very low
incidence of adverse cardiac events during the inhospital stay and 30-day follow-up.
Studies demonstrated that PPCI is a cost-effective
and superior strategy when compared to ﬁbrinolysis
[16,17]. The net beneﬁt of interventional strategy
was achieved mainly because of the lower number
of ACEs and higher permanent coronary reperfusion when compared with ﬁbrinolysis [18e20]. In
addition, coronary intervention results in shorter
hospital stay as well as lower number of revascularization and hospitalizations during the follow-up
period. This might reduce the economic burden
with the extension of the cost net beneﬁt for longer
than 5 years after STEMI, along with an increase in
life expectancy of about 12 months in the PPCI
group [19].
The strategies of transferring patients for PPCI were
analyzed in various randomized clinical trials conﬁrming the superiority of PPCI when compared
with the peripheral hospital ﬁbrinolytic therapy, in
particular when the inherent delay of interventional
strategy is not excessive and is adjusted to that
recommended in international clinical guidelines
[5e8]. One major challenge of PPCI strategy that has
yet to be resolved is the shortage of beds in critical
care units when offering hospital admission for
patients transferred from other non-PPCI centers.
There are limited data on transferring patients back
after PPCI to their referral hospitals. In one study,
Margheri et al [20] described a cohort of 135 patients
treated with PPCI, of whom 92 patients had been
transferred from peripheral hospitals. Interestingly,
81 (88%) of 92 patients could be returned to their
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Table 3. Timing intervals.

Onset of symptoms to balloon time, min
First medical contact to balloon time, min
Procedural time, min
Post PCI in-hospital stay, d

Onsite PCI
(N ¼ 156)

Returned back PCI
(N ¼ 350)

p

312 ± 120
46 ± 35
47 ± 32
3.4 ± 2

366 ± 300
110 ± 67
45 ± 27
4.6 ± 3

0.04
<0.0001
0.8
0.057

Data are presented as mean ± SD.
PCI ¼ percutaneous coronary intervention.
Table 4. Adverse cardiac events.
In-hospital complications

Death
Reinfarction
Bleeding
Minor
Major
Arrhythmias
Ventricular tachycardia/ﬁbrillation
Atrial ﬁbrillation
Atrioventricular block
Stroke
Revascularization
Readmission

30-day follow-up
Onsite PCI
(N ¼ 156)

Returned back PCI
(N ¼ 350)

p

Onsite PCI
(N ¼ 156)

Returned back PCI
(N ¼ 350)

p

0 (0)
1 (0.6)
3 (2)
2 (1.2)
1 (0.6)
5 (3)
1 (0.6)
3 (2)
1 (0.6)
0 (0)
0 (0)
e

1 (0.3)
1 (0.3)
2 (0.6)
2 (0.6)
0 (0)
2 (0.6)
0 (0)
1 (0.3)
1 (0.3)
0 (0)
0 (0)
e

0.8
0.79

1
2
3
2
1
6
1
4
1
0
2
7

1
1
2
2
0
4
0
3
1
0
4
5

0.82
0.68

0.72

0.64
e
e
e

(0.6)
(1.2)
(2)
(1.2)
(0.6)
(3.8)
(0.6)
(2.5)
(0.6)
(0)
(1.2)
(4.5)

(0.3)
(0.3)
(0.6)
(0.6)
(0)
(1.9)
(0)
(1.3)
(0.6)
(0)
(1.1)
(1.5)

0.74

0.8
e
0.9
0.57

Data are presented as n (%).
PCI ¼ percutaneous coronary intervention.

referral centers within 8 hours after the procedure.
Nevertheless, this study was performed in the
percutaneous transluminal coronary angioplasty
era. Also, it was limited by a retrospective design
and no speciﬁc criteria for transfer nor cardiovascular events were speciﬁed.
It is worth noting that our ﬁndings are similar to
those reported in previous studies [11e13], reafﬁrming the safety and feasibility of retransferring
patients after PCI with very low cardiac events;
however, all of the previous studies excluded patients with STEMI. Furthermore, only our study
used the shortest time interval (34 ± 23 min) for
returning patients back to their referring centers.
It is of great importance that no clinical events were
reported during the transfers, and the frequency of
ACEs studied within the hospital stay and at 30-day
follow-up was lower than those previously reported
regarding PPCI treatment [21,22]. Certainly, the low
incidence of vascular and bleeding complications
can be explained by a predominant use of radial
approach in our cohort. Furthermore, the low
number of adverse events should also be related to
the stringent selection process of our patients.
Importantly, we conclude that immediate transfer of
patients post PPCI is safe and feasible once an
adequate ﬂow of communication between the
referring and the PCI-capable hospital is provided.

Notably, the study had been presented and won the
ﬁrst place prize at the Saudi Heart Association
annual meeting in 2019; in addition, the abstract had
been published in the Journal of the Saudi Heart
Association.
4.1. Limitations of the study
This study had several limitations. First, we followed patients for 1 month only, and a longer
follow-up to detect complications is anticipated.
Second, we excluded high-risk patients and
complicated PPCI; thus, our results cannot be
generalized to all patients with STEMI. Finally, our
strategy cannot be applied to other hospitals that do
not have similar facilities and resources (prearranged protocol for immediate transfer, 24/7 PPCI
capabilities, PPCI hospital code, non-PPCI-capable
hospitals located outside 20 km from the tertiarycare center).

5. Conclusions
The immediate return of low-risk STEMI patients is
feasible in the majority of cases. This strategy represents an effective and safe part of the reperfusion
protocol in the low-risk STEMI population with very
low incidence of adverse cardiac events.
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